Disitamab Vedotin for injection

DRUG2 trials

Sponsors

RemeGen Co., Ltd.

Conditions

Breast CancerHigh-risk Non-muscle Invasive Bladder Cancer

Phase 1

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

RecruitingNCT06378242

RemeGen Co., Ltd.High-risk Non-muscle Invasive Bladder Cancer

Start: 2024-06-14End: 2029-12-31Target: 24Updated: 2024-07-11

Phase 2

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

RecruitingNCT06389006

RemeGen Co., Ltd.Breast Cancer

Start: 2024-04-29End: 2026-12-31Target: 79Updated: 2024-05-23

Related Papers

Intravesical Disitamab Vedotin (RC48) for HER2‐Expressing High‐Risk Non‐Muscle‐Invasive Bladder Cancer: A Single‐Arm, Dose–Escalation Phase I Trial Study

MedComm2025-07-013 citations

Intravesical disitamab vedotin (RC48) for patients with HER2-expressing high-risk non-muscle-invasive bladder cancer: A dose-escalation phase I trial.

Journal of Clinical Oncology2025-05-28